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In 2006, a survey of transmitted human immunodeficiency virus (HIV) drug resistance (TDR) was conducted
in Lilongwe, Malawi. The survey followed the World Health Organization method to classify TDR to
nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs),
and protease inhibitors (PIs) among primigravid women aged <25 years. Results of the 2006 survey showed
<5% TDR in all drug classes. In 2009, TDR surveys using the same method were repeated in Lilongwe and
expanded to Blantyre. Findings show that in Lilongwe TDR to NRTIs and PIs was <5%, whereas TDR to
NNRTIs was 5%–15%. In Blantyre, TDR was <5% to all drug classes. Observed moderate TDR in Lilongwe is
cause for concern and signals the need for closer monitoring of Malawi’s antiretroviral therapy program.
Malawi is one of the countries most affected by the hu-
man immunodeficiency virus (HIV) epidemic in Africa,
with an estimated prevalence of 12% among adults aged
15–49 years [1]. The epidemic is predominantly spread
via heterosexual contact, and prevalence estimates in-
dicate that urban areas are more heavily affected than are
rural areas [1].
Malawi provides antiretroviral therapy (ART) free of
charge using a public health approach where tasks are
shifted from more specialized to less specialized health-
care workers and where ART is provided at peripheral
health facilities. Patients are predominantly prescribed
standardized first-line ART regimens and monitored by
nonphysicians using World Health Organization (WHO)
clinical staging guidelines with limited laboratory
monitoring. The first-line ART regimen and 3 alternate
first-line regimens consist of 2 nucleoside reverse transc-
riptase inhibitors (NRTIs) combined with a nonnucleo-
side reverse transcriptase inhibitor (NNRTI). Since 2004,
about 383 000 patients have initiated ART, of whom
277 000 (72%) remained alive and on therapy by June
2011 [2].
Because ART is provided on a massive scale without
the benefit of individual viral load or drug resistance
testing, the emergence and transmission of HIV drug
resistance (HIVDR) remains a fundamental concern.
The lack of individual HIVDR testing has not limited
Malawi’s ability to optimize patient care, and the country
has developed a comprehensive HIVDR prevention and
assessment strategy based on WHO guidance consisting
of routine monitoring of HIVDR early warning indicators
and routine surveillance of transmitted and acquired
HIVDR [3].
Prior to 2007, most African countries reported trans-
mitted HIV drug resistance (TDR) prevalence estimates
of ,5% [4–9] attributed mostly to low ART coverage;
Malawi was no exception, with,5% TDR reported to all
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drug classes in a 2006 survey conducted in Lilongwe [10]. How-
ever, recently, a number of cities in East Africa, including
Entebbe, Uganda, and Kigali, Rwanda, have reported TDR
prevalence of .5% [11]. Southern Africa also has not been
spared, and TDR prevalence of .5% was recently reported in
Cape Town, South Africa, and in Lusaka, Zambia [11, 12].
However, it is noteworthy that studies that have previously
reported TDR prevalence estimates of .5% in this region
have not used the WHO method, making comparison of
results difficult. Despite these methodological differences,
a trend toward increasing TDR prevalence estimates is sup-
ported by a recent meta-analysis by Gupta et al [13], which
reports more countries with moderate (5%–15%) TDR
prevalence after 2007 compared with pre-2007.
The presence of HIVDR prior to ART initiation is an impor-
tant predictor of virological response to antiretroviral regimens
[14, 15]. Therefore, the existence of significant population-level
TDR may undermine the success of the national ART scale-up
initiative. Surveys to classify TDR provide important pro-
grammatic information regarding likely efficacy of future
first-line ART, current pre- and postexposure prophylactic reg-
imens, and HIV prevention programs. The expected prevalence
of TDR partly depends on the extent of ART scale-up and the
duration that antiretroviral drugs (ARVs) have been in use
within a defined geographical area [11, 12].
Blantyre and Lilongwe are 2 major urban areas where ART
was first provided in Malawi and currently have the largest
number of patients on ART; thus, if TDR were to be observed,
it is likely to be seen in these locations. In 2009, TDR surveys
were performed in Lilongwe City and Blantyre City. Results
are reported here.
METHODS
Healthcare facilities within the designated 2 catchment areas
of Lilongwe and Blantyre City were selected if they provided
antenatal care and prevention of mother-to-child transmission
of HIV services and were seeing adequate numbers of pregnant
women in order to contribute to the minimum sample size
(N # 47) within a reasonable period. Additionally, sites were
selected based on capacity to implement the survey, including
ability to perform routine CD4 counts for all newly diagnosed
HIV-positive antenatal attendees. Three health facilities
(Kawale, Area 25, and Bwaila) were selected in Lilongwe, and
2 health facilities (Ndirande and Limbe) were selected in the
Blantyre urban area.
As a proxy for recently HIV-infected individuals, only primi-
gravid women ,25 years without clinical evidence of advanced
HIV infection (only WHO clinical stage 1, as determined by
healthcare providers), who self-reported naivete´ to ARVs and
who tested HIV positive for the first time, were eligible to
participate in the survey. After routine CD4 cell count testing,
remnant blood was used to prepare dried blood spots (DBSs)
from consecutively eligible women.
HIVDR genotyping was performed by the WHO accredited
National HIV and Retrovirology Laboratory, Public Health
Agency, Ottawa, Canada. Complete HIV protease and part of
reverse transcriptase were sequenced using previously described
methods [16].
The WHO TDR survey method permits classification of
TDR as low (,5%), moderate (5%–15%), or high (.15%) in
a specific population in a defined geographic region using
#47 specimens.
For each geographic region, 60 HIV-positive specimens based
on HIV rapid tests performed at the sites were consecutively
collected between January 2009 and April 2009 to generate at
least 47 specimens for genotyping (taking into account a pro-
portion of specimens that would fail to amplify). Due to the
concern for preserving the routine nature of the health systems
at the participating facilities, no behavioral questionnaires were
used. All specimens were prepared, processed, and stored in
Malawi following WHO DBS guidance and were shipped to the
genotyping laboratory for testing [17].
Neighbor-joining distance method was used to assess for
possible contamination, and subtyping was performed using the
REGA subtyping tool [18, 19]. TDR for each drug class was
determined using the 2009 WHO TDR mutations list available




A total of 61 DBS specimens were collected; 54 (88.5%) were
successfully amplified. All sequences were HIV subtype C.
Among the first 47 specimens, 3 had TDR mutations. One
specimen had both NNRTI (G190E) and NRTI (M184V)
mutations. The second specimen had 1 NRTI TDR mutation
(D67DN), and the third specimen had 1 NNRTI TDR mu-
tation (Y188CY). No PI resistance was detected. When these
data were analyzed by drug class as per WHO TDR guidance,
the classification of transmitted resistance was ,5% for
NNRTI, NRTI, and PI drug classes.
Lilongwe Geographical Area
A total of 68 DBS specimens were collected, and 55 (80%)
were successfully amplified. All sequences were HIV subtype C.
Among the first 47 specimens, 3 had 1 detected NNRTI TDR
mutation: K103S, K103N, or V106A. No NRTI or PI mutations
were detected. Following WHO guidance, NNRTI TDR was
classified as moderate (5%–15%), and NRTI and PI TDR was
classified as low (,5%).
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DISCUSSION
ART scale-up began rapidly in Malawi in 2004. Some degree
of HIVDR is inevitable even when appropriate regimens
are prescribed and optimal adherence to treatment is sup-
ported. Routine surveillance of TDR provides important
public health information regarding the efficacy of current
pre- and postexposure prophylaxis and may predict pop-
ulation level efficacy of first-line regimens when recently
infected populations require future ART. As part of its
ART program, Malawi has adopted WHO guidance for the
routine monitoring of site factors associated with the
emergence of HIVDR (HIVDR Early Warning Indicators)
and the routine surveillance of transmitted and acquired
HIVDR.
In 2006, in Lilongwe TDR was classified as low (,5%) for
all drug classes. We observed moderate (5%–15%) NNRTI
TDR in Lilongwe and low TDR (,5%) in Blantyre for all
drug classes. Although specimens were obtained only from
women who were naive to ARVs, it is possible that some did
not disclose previous ART exposures. Nonetheless, the prev-
alence classification of 5%–15% NNRTI TDR in Lilongwe is
troubling and merits attention.
Malawi is one of the first countries in sub-Saharan Africa
to report moderate TDR using the WHO TDR survey
method, although studies that have used other methodologies
have previously suggested similar prevalence estimates in
South Africa and Zambia [11, 12]. In the current survey, new
infections were based on self-reports of drug naivete´, age
,25 years, testing positive for the first time, and primi-
gravidity. This definition of recent infection may not have
high specificity because some women may have falsely re-
ported their characteristics. However, given recent evidence
suggesting that TDR may be increasing in sub-Saharan Africa
[13, 23, 24], these results may truly reflect increasing TDR in
Malawi.
In order to confirm the findings of this survey, surveil-
lance of TDR was repeated in Lilongwe by integrating the
WHO TDR survey method into routine antenatal seros-
urveillance in 2010. Specimens from this follow-up survey
await genotyping. Additionally, in 2011, Malawi plans to
monitor WHO HIVDR early warning indicators in several
regions of the country including Lilongwe and Blantyre in
order to assess clinic function in minimizing the emergence
of possible HIVDR by containing rates of losses to follow-up,
ensuring drug supply continuity, and maximizing patient
adherence. In addition, as high rates of loss to follow-up
have previously been identified as problematic in Malawi,
a special survey to characterize reasons for loss to follow-up
and assess strategies to link patients back into care is planned
for 2012.
CONCLUSIONS
In conclusion, although findings of moderate TDR merit at-
tention and warrant concern, these results must be treated
cautiously. Survey results showing moderate TDR to the NNRTI
drug class are insufficient to support changing current ART
guidelines in Malawi but do signal the importance of robust
programmatic monitoring of factors known to be associated
with the emergence of HIVDR at all ART sites in Malawi and
the need for routine surveillance of transmitted and acquired
HIVDR. Additionally, results highlight the need to evaluate and
possibly strengthen prevention messages geared to populations
receiving ART and to populations recently diagnosed with HIV
who are not yet eligible to initiate ART in order to both mini-
mize HIV and HIVDR transmission.
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